TNFSF4
Tumor necrosis factor ligand superfamily member 4
As of the edition of 20 October 2026, TNFSF4 (tumor necrosis factor ligand superfamily member 4, UniProt P23510) has 3 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23510
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Digestive system; Infections; Nutrition and metabolism
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Amlitelimab | Active | Phase 3 | none listed |
| SAR442970 | Active | Phase 2 | none listed |
| Oxelumab | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Roche | Route A |
The other 2 companies at TNFSF4
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at TNFSF4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.